Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.
Also called NCT05983770
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 127 participants
- Sponsor
- Registry
-
NCT05983770
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Brazil, Canada, France, Germany, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05983770. Randomized; no masking; primary purpose treatment. Start 2023-08-30 (actual); primary completion 2025-09-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
- Condition
- Kidney Transplant Rejection
- Intervention (Drug)
- AT-1501
- Intervention (Drug)
- Tacrolimus
- Lead sponsor
- Eledon Pharmaceuticals
Record details
- Record id
cardio:ct-nct05983770- Content hash
ebc395ca4be706d25518da01b6fe71281f3b28ee62be5d7b50fe5577d2aa742f